<DOC>
	<DOCNO>NCT00129922</DOCNO>
	<brief_summary>The efficacy adjuvant chemotherapy limit patient high risk recurrence . Also , axillary positive node patient , optimum chemotherapy regimen still discussion . Some previous study suggest , subset node-positive patient , treatment base sequential administration anthracyclines taxanes efficient . Paclitaxel dose-dense ( weekly ) administration render improve therapeutic index ( activity/toxicity ) . The study design compare 6 course FEC scheme ( 600/90/600 ) , combination proven efficacy node positive breast cancer patient , versus 4 FEC course follow 8 weekly paclitaxel administration ( 100mg/m2 ) . The study hypothesis 5-year disease-free survival control arm 60 % . The investigator expect increase 8 % experimental treatment . With alpha error 0.05 , 80 % power , post-randomization estimate drop-out rate 10 % , 1250 patient need , 625 per arm .</brief_summary>
	<brief_title>Fluorouracil , Epirubicin , Cyclophosphamide ( FEC ) Versus FEC Plus Paclitaxel Adjuvant Treatment Node Positive Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Written inform consent . Histological diagnosis breast cancer . Node positive operable breast cancer ( stage IIIII ) . Breast cancer surgery , consist radical mastectomy conservative surgery , plus lymphadenectomy least 6 extirpated node . Surgery must happen 8 week prior randomisation . Age &gt; =18 &lt; = 70 year old . Negative pregnancy test . Adequate contraceptive method study participation . Performance status 90100 ( Karnofsky index ) ECOG &lt; =1 . Haemoglobin &gt; = 10 g/dl ; neutrophil &gt; 1,500/cc ; platelet &gt; 100,000/cc . Adequate hepatic function bilirubin , SGOT SGPT &lt; 1.5 x upper normal limit ( UNL ) . Adequate cardiac function document leave ventricular ejection fraction ( LVEF ) . Adequate renal function creatinine &lt; 1.5 mg/dl . Previous chemotherapy , hormone therapy and/or radiotherapy breast cancer . Bilateral breast cancer . Lobular situ carcinoma . Previous current malignancy , except basal skin carcinoma , cervical situ carcinoma superficial bladder carcinoma , adequately treat . History arrhythmias and/or congestive heart failure cardiac blocking grade 23 ; history myocardial infarction 6 month recruitment . Inability treatment study compliance . Pregnant lactating woman . Active infection . History hypersensitivity cremophor cyclosporine . Preexisting grade 2 motor sensorial neurotoxicity ( National Cancer Institute Common Toxicity Criteria [ NCI CTC ] ) . Hormonal receptor status determine . Any criterion , investigator â€™ opinion , may jeopardize patient 's security compliance . Administration investigational product 30 day prior randomisation ; current participation another clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Axillary node positive breast cancer .</keyword>
	<keyword>Sequential drug administration .</keyword>
	<keyword>Weekly paclitaxel .</keyword>
</DOC>